07:17 AM EDT, 05/22/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Thursday it initiated a phase 4 trial at Massachusetts General Hospital to evaluate the safety and efficacy of two dosing levels of purified Cortrophin gel in treating acute gout flares.

The company said Cortrophin gel is approved for short-term use as an adjunct therapy during acute episodes of gouty arthritis but is not for intravenous administration.

The study aims to further assess its clinical benefits and inform optimal dosing strategies, it added.